| Literature DB >> 33211074 |
Frank Brodie1,2, Michael Repka3, Stephen Allan Burns4, S Grace Prakalapakorn5, Christie Morse5, Joel S Schuman6, Michael R Duenas7, Natalie Afshari8, John S Pollack9, Jennifer E Thorne10, Albert Vitale10, H Nida Sen10, David Myung1, Mark S Blumenkranz1, Elmer Tu11, Daniel X Hammer12, Michelle Tarver12, Bradley Cunningham12, Larry Kagemann12, SriniVas Sadda13, David Sarraf13, Glenn J Jaffe13, Malvina Eydelman11.
Abstract
In April 2019, the US Food and Drug Administration, in conjunction with 11 professional ophthalmic, vision science, and optometric societies, convened a forum on laser-based imaging. The forum brought together the Food and Drug Administration, clinicians, researchers, industry members, and other stakeholders to stimulate innovation and ensure that patients in the US are the first in the world to have access to high-quality, safe, and effective medical devices. This conference focused on the technology, clinical applications, regulatory issues, and reimbursement issues surrounding innovative ocular imaging modalities. Furthermore, the emerging role of artificial intelligence in ophthalmic imaging was reviewed. This article summarizes the presentations, discussion, and future directions.Entities:
Mesh：
Year: 2021 PMID： 33211074 PMCID： PMC8005310 DOI： 10.1001/jamaophthalmol.2020.4994
Source DB: PubMed Journal: JAMA Ophthalmol ISSN： 2168-6165 Impact factor: 7.389